Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol

NDT Plus

Volumn 3, Issue 3, 2010, Pages 285-287

  Elmholdt, Tina Rask ^a   Jørgensen, Bettina ^a   Ramsing, Mette ^a   Pedersen, Michael ^a   Olesen, Anne Braae ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

chronic kidney disease; contrast enhanced MRI; gadobutrol; nephrogenic systemic fibrosis

Indexed keywords

CREATININE; GADOBUTROL; GADODIAMIDE;

ADULT; ARTICLE; BLOOD SAMPLING; CASE REPORT; CHRONIC KIDNEY DISEASE; DIET; DRUG EXPOSURE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PUNCH BIOPSY;

EID: 77955954288     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfq028     Document Type: Article

References (10)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000-1001
2. Grobner T, Prischl FC. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. Semin Dial 2008; 21: 135-139
3. Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008; 158: 273-280
4. Marckmann P, Skov L, Rossen K et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-2362
5. Swaminathan S, HighWA, Ranville J et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 2008; 73: 1413-1418
6. Cowper SE, Rabach M, Girardi M. Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 2008; 66: 191-199
7. Bangsgaard N, Marckmann P, Rossen K, Skov L. Nephrogenic systemic fibrosis: late skin manifestations. Arch Dermatol 2009; 145: 183-187
8. Penfield JG, Reilly RF. Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents? Semin Dial 2008; 21: 129-134
9. Idee JM, Port M, Robic C, Medina C, Sabatou M, Corot C. Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging 2009; 30: 1249-1258
10. Wollanka H, Weidenmaier W, Giersig C. NSF after Gadovist exposure: a case report and hypothesis of NSF development. Nephrol Dial Transplant 2009; 24: 3882-3884